Warning Letter Record: International Medication Systems Limited (2026-07-02) — CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
Key takeaway: The FDA's Center for Drug Evaluation and Research (CDER) issued Warning Letter 320-26-99 on July 2, 2026, to International Medication Systems Limited (FEI 2016148, South El Monte, CA) following a December 9-19, 2025 inspection identifying significant CGMP violations for finished pharmaceuticals. The FDA documented failures to adequately investigate batch discrepancies and contamination events—notably too-numerous-to-count microbial growth and insect larvae found in environmental monitoring of an epinephrine injection lot (EA038A5) and adjacent ISO 7 area—which the firm attributed to post-exposure contamination without scientific support and released despite contamination risks; the firm also received over 90 customer complaints since December 2023 related to container-closure defects with investigations frequently closed without root cause identification. The FDA required submission of a comprehensive third-party assessment of the firm's deviation investigation system and a detailed remediation plan addressing investigation competencies, root cause analysis, CAPA effectiveness, quality unit oversight, and written procedures.
Argus analysis
# FDA Warning Letter Analysis: International Medication Systems Limited
**The Company and Findings**
International Medication Systems Limited, a finished pharmaceutical manufacturer in South El Monte, California (FEI 2016148), received a warning letter from the FDA's Center for Drug Evaluation and Research on July 2, 2026, following an inspection conducted December 9–19, 2025. The FDA determined that the company's drug products are adulterated because manufacturing methods, facilities, and controls fail to meet Current Good Manufacturing Practice standards. The inspection identified critical failures in contamination control during aseptic processing of sterile injectable products, including epinephrine injection.
**Regulatory Citations and Their Significance**
The warning letter cites violations of 21 CFR parts 210 and 211, the foundational CGMP regulations for pharmaceutical manufacturing. Specifically, 21 CFR 211.192 requires thorough investigation of batch discrepancies and specification failures; the company inadequately investigated too-numerous-to-count microbial contamination and insect larvae discovered in environmental monitoring plates during epinephrine production. Additionally, 21 CFR 211.42(c)(10) and 211.113(b) mandate adequate facility design and written procedures to prevent contamination in aseptic areas. The FDA found the company's restricted access barrier systems (RABS) lacked fundamental design elements, requiring operators to manually handle approximately 200+ stopper bags per batch within critical ISO 5 areas—a high-risk intervention without adequate environmental monitoring.
**Response Timeline and Industry Observations**
The company submitted a response on January 15, 2026, which the FDA deemed inadequate. Compliance officers in sterile manufacturing should monitor whether International Medication Systems submits a revised response addressing the specific deficiencies: third-party assessments of deviation investigation systems, CAPA program remediation, comprehensive field alert and complaint re-investigation, and pest control program review. The two-year facility upgrade timeline proposed by the company will likely face regulatory skepticism given the severity of findings and history of over 90 complaints since December 2023 related to contamination and container-closure defects.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER International Medication Systems Limited MARCS-CMS 727560 — July 02, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Reference #: 320-26-99 Product: Drugs Recipient: Recipient Name Dr. Jack Y. Zhang Recipient Title Chief Executive Officer International Medication Systems Limited 1886 Santa Anita Avenue South El Monte , CA 91733 United States Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-99 July 2, 2026 Dear Dr. Zhang: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, International Medication System Limited, FEI 2016148, at 1886 Santa Anita Avenue, South El Monte, from December 9 to 19, 2025. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your January 15, 2026, response to our Form FDA 483 in detail. During our inspection, our investigators observed specific violations including, but not limited to, the following. 1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192). Your firm manufactures active pharmaceutical ingredients and sterile injectable drug products. The sterile injectable products include aseptically filled (b)(4) . Your firm failed to conduct adequate investigations. For example, you inadequately investigated multiple too-numerous-to-count (TNTC) microbial findings during the manufacture of epinephrine injection, lot EA038A5. Specifically, a viable air environmental monitoring plate, located next to the (b)(4) in your ISO 5 aseptic filling area, yielded a too-numerous-to-count result with confluent bacterial growth and numerous insect larvae. On the same day, personnel monitoring plates for an individual in the adjacent ISO 7 (b)(4) also yielded TNTC results and contained insect larvae. Your investigation failed to identify a scientifically-supported root cause, instead attributing these exceedingly high environmental monitoring findings to an unsubstantiated hypothesis involving insect infiltration of sealed monitoring plates. Notably, written procedures require inspection of plates before use to ensure they are not contaminated or defective, and also require very strict handling measures following sampling (e.g., (b)(4) bags, sterile tape). The microbiological growth media batch also passed negative control testin…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What FDA violations was International Medication Systems Limited cited for?
- The FDA Warning Letter to International Medication Systems Limited (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/Finished Pharmaceuticals/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to International Medication Systems Limited?
- FDA issued the letter (MARCS-CMS 727560) on 2026-07-02 and posted it publicly on fda.gov on 2026-07-14.
- Is the FDA warning letter to International Medication Systems Limited publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/international-medication-systems-limited-727560-07022026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Warning Letter Record: International Medication Systems Limited (2026-07-02) — CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-international-medication-systems-limited-2026-07-02-cgmp
"Warning Letter Record: International Medication Systems Limited (2026-07-02) — CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-international-medication-systems-limited-2026-07-02-cgmp.
Argus HQ Research. "Warning Letter Record: International Medication Systems Limited (2026-07-02) — CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire LLC. Accessed July 15, 2026. https://argushq.ai/fda/warning-letter/fda-wl-international-medication-systems-limited-2026-07-02-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_international_medication_systems_limited_2026_07_02_cgmp_2026,
title = {Warning Letter Record: International Medication Systems Limited (2026-07-02) — CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-international-medication-systems-limited-2026-07-02-cgmp},
note = {Accessed: July 15, 2026}
}